Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Medexus Pharmaceuticals Inc (MDP.TO)

Medexus Pharmaceuticals Inc (MDP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 61,314
  • Shares Outstanding, K 24,526
  • Annual Sales, $ 113,054 K
  • Annual Income, $ -214 K
  • 60-Month Beta 2.47
  • Price/Sales 0.40
  • Price/Cash Flow 1.91
  • Price/Book 1.38
Trade MDP.TO with:
  • Price/Earnings ttm 45.98
  • Earnings Per Share ttm 0.04
  • Most Recent Earnings $0.08 on 08/07/24
  • Next Earnings Date 11/13/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.00
  • Number of Estimates 3
  • High Estimate 0.04
  • Low Estimate -0.03
  • Prior Year -0.08
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.12 +19.81%
on 09/16/24
2.75 -7.64%
on 09/05/24
+0.13 (+5.39%)
since 08/20/24
3-Month
1.60 +58.75%
on 06/21/24
2.75 -7.64%
on 09/05/24
+0.90 (+54.88%)
since 06/20/24
52-Week
1.44 +76.39%
on 12/04/23
3.39 -25.07%
on 10/02/23
-0.47 (-15.61%)
since 09/20/23

Most Recent Stories

More News
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders...

MEDXF : 1.8650 (+1.08%)
MDP.TO : 2.54 (+1.60%)
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization rights...

MEDXF : 1.8650 (+1.08%)
MDP.TO : 2.54 (+1.60%)
Medexus Announces Strong Fiscal Q1 2025 Results

Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 millionManagement to host conference call at 8:00 AM Eastern time on...

MEDXF : 1.8650 (+1.08%)
MDP.TO : 2.54 (+1.60%)
Medexus Schedules First Fiscal Quarter 2025 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August...

MEDXF : 1.8650 (+1.08%)
MDP.TO : 2.54 (+1.60%)
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024

FDA has Accepted for Review the Treosulfan NDAManagement to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024)...

MEDXF : 1.8650 (+1.08%)
MDP.TO : 2.54 (+1.60%)
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26,...

MEDXF : 1.8650 (+1.08%)
MDP.TO : 2.54 (+1.60%)
FDA Accepts for Review Treosulfan NDA Resubmission

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization...

MEDXF : 1.8650 (+1.08%)
MDP.TO : 2.54 (+1.60%)
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®....

MEDXF : 1.8650 (+1.08%)
MDP.TO : 2.54 (+1.60%)
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the...

MEDXF : 1.8650 (+1.08%)
MDP.TO : 2.54 (+1.60%)
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age groupToronto, Ontario and Chicago, Illinois--(Newsfile...

MEDXF : 1.8650 (+1.08%)
MDP.TO : 2.54 (+1.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases,...

See More

Key Turning Points

3rd Resistance Point 2.60
2nd Resistance Point 2.56
1st Resistance Point 2.53
Last Price 2.54
1st Support Level 2.46
2nd Support Level 2.42
3rd Support Level 2.39

See More

52-Week High 3.39
Fibonacci 61.8% 2.65
Last Price 2.54
Fibonacci 50% 2.41
Fibonacci 38.2% 2.18
52-Week Low 1.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar